Here is more about brentuximab vedotin, a promising therapy agent being developed by Millennium Pharmaceuticals.  I found this on a business Website called RTT News:
Drug-Antibody Conjugate Tests Well Against Lymphoma

by RTT Staff Writer

A new report published in the November 4 edition of the New England Journal of Medicine suggests that a newly developed drug-antibody conjugate is showing promise in the treatment of various lymphomas.

For the study, Dr. Anas Younes of the University of Texas in Houston examined 45 lymphoma patients who were already receiving chemotherapy. With the edition of the new conjugate, called brentuximab vedotin, 85 percent of the patients experienced a regression in their lymphoma.

According to a new report from, 11 of the 45 patients enjoyed a complete remission with the new conjugate, while an additional six saw a partial remission. Younes also found that 13 of 16 patients who displayed baseline symptoms enjoyed a complete reversal of symptoms with brentuximab vedotin.

The conjugate was given intravenously every three weeks and dosage levels were monitored at each administration. Progress was reviewed every six weeks.

Here is a link to another story I did about brentuximab vedotin.  And while I’m at it, here is an additional link to a press release about the new drug from Millinnium.
Feel good and keep smiling!  Pat

Leave a Reply